195 related articles for article (PubMed ID: 1305630)
1. L-tryptophan in neuropsychiatric disorders: a review.
Sandyk R
Int J Neurosci; 1992; 67(1-4):127-44. PubMed ID: 1305630
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan supplementation and serotonin function: genetic variations in behavioural effects.
Gibson EL
Proc Nutr Soc; 2018 May; 77(2):174-188. PubMed ID: 29368666
[TBL] [Abstract][Full Text] [Related]
3. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Ko WK; Li Q; Bezard E
Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
[TBL] [Abstract][Full Text] [Related]
4. Serotonin-dopamine interaction: an overview.
Esposito E; Di Matteo V; Di Giovanni G
Prog Brain Res; 2008; 172():3-6. PubMed ID: 18772025
[TBL] [Abstract][Full Text] [Related]
5. [Psychopharmacology of tryptophan (author's transl)].
Poitou P; Boulu R
Pathol Biol (Paris); 1977 Oct; 25(8):565-71. PubMed ID: 339170
[TBL] [Abstract][Full Text] [Related]
6. Effect of diet on serotonergic neurotransmission in depression.
Shabbir F; Patel A; Mattison C; Bose S; Krishnamohan R; Sweeney E; Sandhu S; Nel W; Rais A; Sandhu R; Ngu N; Sharma S
Neurochem Int; 2013 Feb; 62(3):324-9. PubMed ID: 23306210
[TBL] [Abstract][Full Text] [Related]
7. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
8. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
Kozell L; Sandyk R; Wagner GC; Fisher H
Life Sci; 1987 Oct; 41(14):1739-44. PubMed ID: 3657380
[TBL] [Abstract][Full Text] [Related]
9. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology.
Reilly JG; McTavish SF; Young AH
J Psychopharmacol; 1997; 11(4):381-92. PubMed ID: 9443529
[TBL] [Abstract][Full Text] [Related]
10. [Nicotine in neuropsychiatric movement disorders].
Erdmann R
Fortschr Neurol Psychiatr; 1996 Sep; 64(9):362-6. PubMed ID: 8991874
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications.
Russo S; Kema IP; Bosker F; Haavik J; Korf J
World J Biol Psychiatry; 2009; 10(4):258-68. PubMed ID: 19921967
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan depletion and its implications for psychiatry.
Bell C; Abrams J; Nutt D
Br J Psychiatry; 2001 May; 178():399-405. PubMed ID: 11331552
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments: replacement therapy with choline or lecithin in neurological diseases.
Barbeau A
Can J Neurol Sci; 1978 Feb; 5(1):157-60. PubMed ID: 148319
[TBL] [Abstract][Full Text] [Related]
14. Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior.
Brett PM; Curtis D; Robertson MM; Gurling HM
Am J Psychiatry; 1995 Mar; 152(3):437-40. PubMed ID: 7864272
[TBL] [Abstract][Full Text] [Related]
15. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
[TBL] [Abstract][Full Text] [Related]
16. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
Voon V; Fernagut PO; Wickens J; Baunez C; Rodriguez M; Pavon N; Juncos JL; Obeso JA; Bezard E
Lancet Neurol; 2009 Dec; 8(12):1140-9. PubMed ID: 19909912
[TBL] [Abstract][Full Text] [Related]
17. Role of serotonin in therapy of depression and related disorders.
Fuller RW
J Clin Psychiatry; 1991 May; 52 Suppl():52-7. PubMed ID: 1674251
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin: role in psychiatric and neurological diseases.
Cáceda R; Kinkead B; Nemeroff CB
Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
[TBL] [Abstract][Full Text] [Related]
19. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
[TBL] [Abstract][Full Text] [Related]
20. Neurological complications of psychiatric drugs: clinical features and management.
Haddad PM; Dursun SM
Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():15-26. PubMed ID: 18098217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
